Correct Answer: A. Oxidises uric acid
Pegloticase is a recombinant uricase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and readily excretable metabolite. This is the only mechanism that directly breaks down the uric acid molecule itself. In tumor lysis syndrome (TLS), massive cell death releases intracellular contents, causing hyperuricemia that precipitates in renal tubules, leading to acute kidney injury. Pegloticase bypasses the xanthine oxidase pathway entirely—it works downstream, converting the already-formed uric acid into allantoin, which is 5–10 times more soluble than uric acid and rapidly cleared by the kidneys. This is particularly valuable in severe hyperuricemia (>12 mg/dL) or when xanthine oxidase inhibitors (allopurinol, febuxostat) have failed or are contraindicated. The "peg" prefix indicates polyethylene glycol conjugation, which reduces immunogenicity and extends half-life. In Indian clinical practice, pegloticase is reserved for refractory cases of TLS or severe gout because of cost and the need for IV administration, but its mechanism—direct oxidative degradation of uric acid—is pathognomonic and distinct from all other urate-lowering agents.
Why the other options are wrong
B. Xanthine oxidase inhibition — This is the mechanism of allopurinol and febuxostat, which block the conversion of hypoxanthine and xanthine to uric acid, preventing uric acid formation. Pegloticase does not inhibit xanthine oxidase; it acts on already-formed uric acid. NBE traps students who confuse pegloticase with xanthine oxidase inhibitors—a common error because both are used in hyperuricemia, but they work at different points in the purine degradation pathway. C. Excretion of uric acid — Uricosuric agents like probenecid and lesinurad increase renal excretion of uric acid unchanged, without metabolizing it. While pegloticase's product (allantoin) is ultimately excreted, pegloticase itself does not promote uric acid excretion—it chemically transforms uric acid. This option describes the mechanism of uricosuric drugs, not enzymatic degradation. D. Urat-1 receptor inhibition — URAT-1 (urate transporter 1) inhibitors like lesinurad block renal reabsorption of uric acid, increasing urinary loss. Pegloticase has no interaction with URAT-1 transporters. This option conflates renal transport modulation with enzymatic catabolism—a distractor for students who remember that urate transporters are therapeutic targets but confuse the mechanism.
High-Yield Facts
- Pegloticase oxidizes uric acid to allantoin, which is 5–10 times more soluble and rapidly renally cleared.
- Allantoin is the end product of uric acid catabolism in most mammals; humans lack uricase, making pegloticase a recombinant replacement enzyme.
- Pegloticase is reserved for refractory hyperuricemia (>12 mg/dL) or when xanthine oxidase inhibitors fail, due to cost and IV-only administration.
- Polyethylene glycol (PEG) conjugation reduces immunogenicity and extends pegloticase half-life, allowing less frequent dosing.
- In tumor lysis syndrome, pegloticase is preferred over allopurinol when rapid uric acid reduction is critical to prevent acute kidney injury.
Mnemonics
PUMA: Pegloticase Uric acid Metabolism Approach Pegloticase = Uric acid Metabolism (direct oxidation to allantoin). Remember: Pegloticase breaks down uric acid; allopurinol blocks its formation. Three Tiers of Urate-Lowering Therapy Tier 1 (Prevention): Xanthine oxidase inhibitors (block formation). Tier 2 (Excretion): Uricosurics (increase loss). Tier 3 (Degradation): Pegloticase (oxidize to allantoin). Use when Tiers 1–2 fail.
NBE Trap
NBE pairs pegloticase with "xanthine oxidase inhibition" to trap students who know pegloticase is used in severe hyperuricemia but confuse it with allopurinol—the most commonly prescribed urate-lowering agent. The key discriminator is that pegloticase acts downstream (on uric acid itself), not upstream (on xanthine oxidase).
Clinical Pearl
In Indian tertiary centers managing oncology patients with TLS, pegloticase is increasingly used as a second-line agent when allopurinol + hydration fail to control uric acid in the first 24–48 hours. Its ability to rapidly oxidize uric acid to the highly soluble allantoin can prevent dialysis-dependent acute kidney injury in aggressive malignancies (lymphomas, leukemias).
_Reference: KD Tripathi Pharmacology Ch. 16 (Drugs for Gout & Hyperuricemia); Harrison Principles of Internal Medicine Ch. 356 (Gout, Pseudogout, and Related Disorders)_